Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Atropine-neostigmine mixture: a dose-response study.

M Naguib1, M Gomaa

  • 1Department of Anaesthesiology, King Saud University, King Khalid University Hospital, Riyadh, Saudi Arabia.

Canadian Journal of Anaesthesia = Journal Canadien D'Anesthesie
|July 1, 1989
PubMed
Summary

This study determined atropine doses needed to prevent neostigmine-induced bradycardia after pancuronium blockade. Higher atropine doses than typically used may be necessary to avoid late heart rate reductions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Numerical simulation and design recommendations for prestressed steel stayed columns subjected to static and dynamic effects.

Scientific reports·2025
Same author

Applying of SP, DC-Resistivity, DC-TDIP and TDEM soundings in high saline coastal aquifer.

Heliyon·2021
Same author

Targeted next generation sequencing identifies somatic mutations in a cohort of Egyptian breast cancer patients.

Journal of advanced research·2020
Same author

Neostigmine-induced weakness after sugammadex - a reply.

Anaesthesia·2019
Same author

Neostigmine-induced weakness: what are the facts?

Anaesthesia·2018
Same author

Sugammadex-induced bradycardia and asystole: how great is the risk?

British journal of anaesthesia·2018

Area of Science:

  • Anesthesiology and Pharmacology
  • Cardiovascular Physiology

Background:

  • Neostigmine is used to reverse neuromuscular blockade but can cause bradycardia.
  • Atropine is often co-administered to mitigate this effect.
  • Optimal atropine dosing to prevent late-onset bradycardia requires further investigation.

Purpose of the Study:

  • To determine the dose-response relationship of atropine in preventing neostigmine-induced bradycardia.
  • To establish the effective dose 50 (ED50) and effective dose 95 (ED95) of atropine.
  • To compare atropine requirements at different neostigmine doses.

Main Methods:

  • Seventy patients undergoing reversal of pancuronium-induced neuromuscular blockade were studied.
  • Patients received fixed doses of neostigmine mixed with varying doses of atropine.

Related Experiment Videos

  • Heart rates were monitored, and dose-response curves for atropine were constructed at 5 and 10 minutes post-injection.

    • Main Results:

    • Dose-response curves for atropine were parallel in both neostigmine groups.
    • The calculated ED50 and ED95 values for atropine were similar across neostigmine dose groups.
    • Estimated ED50 doses ranged from 0.031 to 0.037 mg/kg, and ED95 doses ranged from 0.046 to 0.06 mg/kg.

    Conclusions:

    • Atropine effectively prevents neostigmine-induced bradycardia.
    • The required atropine doses (ED50 and ED95) were similar regardless of the neostigmine dose used.
    • To prevent late heart rate reductions, atropine doses greater than commonly administered may be necessary.